Literature DB >> 6248202

Uridine kinase, adenylate kinase, and guanase in human lung tumors.

O Greengard, J F Head, S L Goldberg.   

Abstract

In pulmonary neoplasms, the uridine kinase concentration was higher (2- to 20-fold) than in the noninvolved lung portions of each of the 12 subjects studied. The extent of elevation of uridine kinase in the different tumors showed a significant positive correlation with the rises (1.5- to 30-fold) in thymidine kinase, suggesting that neoplastic transformation in human lung involved coordinated increases in the capacity for the reutilization of different nucleoside phosphates. Adenylate kinase was always at lower levels in neoplasms compared to noninvolved areas of the same lung, and the extent of this loss in the different tumors correlated inversely with the gain in uridine kinase and thymidine kinase. Normal fetal human lung was also deficient in adenylate kinase, while its uridine kinase and thymidine kinase (and also guanase) activities were above the adult levels. The guanase activities of the different neoplasms, unrelated to their uridine kinase or thymidine kinase content, correlated with the activities in the subjects' noninvolved lung. These individual differences were much more striking than those between the neoplastic and control samples. Variations in guanase activity thus appear to be "random," whereas observations on the three other enzymes attest to the orderly nature of biochemical differences among individual tumors and between normal and neoplastic lung.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6248202

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  A novel transition state analog inhibitor of guanase based on azepinomycin ring structure: Synthesis and biochemical assessment of enzyme inhibition.

Authors:  Saibal Chakraborty; Niti H Shah; James C Fishbein; Ramachandra S Hosmane
Journal:  Bioorg Med Chem Lett       Date:  2010-11-27       Impact factor: 2.823

2.  Simple oxygraphic analysis for the presence of adenylate kinase 1 and 2 in normal and tumor cells.

Authors:  Aleksandr Klepinin; Lyudmila Ounpuu; Rita Guzun; Vladimir Chekulayev; Natalja Timohhina; Kersti Tepp; Igor Shevchuk; Uwe Schlattner; Tuuli Kaambre
Journal:  J Bioenerg Biomembr       Date:  2016-11-17       Impact factor: 2.945

3.  Analogs of iso-azepinomycin as potential transition-state analog inhibitors of guanase: synthesis, biochemical screening, and structure-activity correlations of various selectively substituted imidazo[4,5-e][1,4]diazepines.

Authors:  Saritha Tantravedi; Saibal Chakraborty; Niti H Shah; James C Fishbein; Ramachandra S Hosmane
Journal:  Bioorg Med Chem       Date:  2013-07-11       Impact factor: 3.641

4.  Integrated analysis of mRNA, microRNA and protein in systemic lupus erythematosus-specific induced pluripotent stem cells from urine.

Authors:  Donge Tang; Yuyu Chen; Huiyan He; Jianrong Huang; Wenbiao Chen; Wujian Peng; Qianjin Lu; Yong Dai
Journal:  BMC Genomics       Date:  2016-07-11       Impact factor: 3.969

5.  c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma.

Authors:  Yari Ciribilli; Prashant Singh; Alberto Inga; Jürgen Borlak
Journal:  Oncotarget       Date:  2016-10-04

6.  Metabolic remodeling in human colorectal cancer and surrounding tissues: alterations in regulation of mitochondrial respiration and metabolic fluxes.

Authors:  Vladimir Chekulayev; Kati Mado; Igor Shevchuk; Andre Koit; Andrus Kaldma; Aleksandr Klepinin; Natalja Timohhina; Kersti Tepp; Manana Kandashvili; Lyudmila Ounpuu; Karoliina Heck; Laura Truu; Anu Planken; Vahur Valvere; Tuuli Kaambre
Journal:  Biochem Biophys Rep       Date:  2015-08-29

7.  Oral cancer cells may rewire alternative metabolic pathways to survive from siRNA silencing of metabolic enzymes.

Authors:  Min Zhang; Yang D Chai; Jeffrey Brumbaugh; Xiaojun Liu; Ramin Rabii; Sizhe Feng; Kaori Misuno; Diana Messadi; Shen Hu
Journal:  BMC Cancer       Date:  2014-03-25       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.